ReviewDiagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology
Introduction
Primary CNS lymphomas are extranodal, malignant non-Hodgkin lymphomas of the diffuse large B-cell type that are confined to the brain, eyes, leptomeninges, or spinal cord, in the absence of systemic lymphoma. Primary CNS lymphomas are estimated to account for up to 1% of all lymphomas, 4–6% of all extranodal lymphomas, and about 3% of all CNS tumours.1 After a continuous rise in the incidence of primary CNS lymphoma during the 1980s and 1990s, epidemiological data in high-income countries show a decrease in incidence, particularly among young patients with AIDS.2 By contrast, the incidence of primary CNS lymphoma continues to rise in elderly patients, who represent most patients in immunocompetent populations.3, 4, 5
Although the prognosis of primary CNS lymphoma remains poor, it has substantially improved in the past two decades as a result of better treatment strategies with a curative aim. However, treatment of this disease remains challenging because, despite high chemosensitivity and radiosensitivity, remissions are frequently of short duration. The blood–brain barrier limits the access of many drugs to the CNS. Furthermore, elderly patients are at especially high risk for the development of severe neurotoxic effects related to treatment.
Optimum treatment recommendations result mainly from retrospective series or single-arm phase 2 studies. Only three completed randomised trials are available for primary CNS lymphoma: one phase 3 and two phase 2 trials.6, 7, 8 The objective of this guideline is to provide clinicians with evidence-based recommendations and consensus expert opinions for the management of patients with this disease. The guidelines focus exclusively on immunocompetent populations, which represent most patients. Primary CNS lymphoma in immunodeficient patients and rare, indolent, low-grade lymphomas that occur mainly in the CNS have a distinct pathogenesis with separate diagnostic and therapeutic implications, and will be subject to specific guidelines, beyond the scope of this Review.
Section snippets
Search strategy and selection criteria
The task force was established in 2013 under the auspices of the European Assocation for Neuro-Oncology and represents European-based medical experts from eleven countries. The task force included specialists in the management of primary CNS lymphoma—including neurologists, haematologists, medical oncologists, neurosurgeons, pathologists, ophthalmologists, and radiation oncologists. Based on best available evidence from literature review, the writing group (EB, JB, AFH, KH-X, MP, RR, US, TS,
General recommendations
Consensus statements and recommendations were given for the following aspects of primary CNS lymphoma: pathology, genetics, clinical presentation, diagnostic confirmation, neuropathological changes of corticosteroid-treated primary CNS lymphoma, neuroimaging, cerebrospinal fluid analyses, vitreous analyses, staging, prognostic factors, response criteria to treatment, and treatment-related neurotoxic effects. Consensus statements and recommendations for the general approach to patients with
Surgery
Although few data are available in the scientific literature, surgery has traditionally been deemed to have no role in the treatment of primary CNS lymphoma. This widely adopted opinion is based on small retrospective series, the results of which suggest no clear benefits in the outcome of surgical resection when used as a sole treatment, compared with supportive care (class IIIb)9 and compared with evidence from biopsy samples from patients who received postoperative chemotherapy or
Systemic chemotherapy
The CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) regimen routinely used for widespread non-Hodgkin lymphomas induces responses of brief duration in patients with primary CNS lymphoma. CHOP added to radiotherapy has likewise not improved patient survival in prospective trials (class IIb).14, 15, 16 This inefficacy is probably because the metabolite of cyclophosphamide, phosphoramide mustard, and doxorubicin are not able to cross the blood–brain barrier and therefore eradicate
Intrathecal chemotherapy
Chemotherapeutic drugs given intrathecally have not been prospectively studied. Therefore, their clinical effectiveness in primary CNS lymphoma is controversial. Results of three retrospective studies30, 31, 32 showed that patients given high-dose methotrexate did not benefit from the additional treatment with methotrexate and cytarabine given intrathecally (class IIIb). By contrast, results from two consecutive single-arm trials33, 34 using the same systemic polychemotherapy regimen suggested
Rituximab
The anti-CD20 antibody rituximab has poor CNS penetration because of its large size. Therefore, the highest concentration and resultant efficacy of rituximab probably occurs during the early treatment phase when the integrity of the blood–brain barrier is reduced at the location of the contrast-enhancing tumours. The effect of rituximab when used as monotherapy in patients with primary CNS lymphoma was assessed in a study in which 12 patients with refractory or relapsed primary CNS lymphoma
Radiotherapy
Because of the microscopically diffuse and multifocal nature of primary CNS lymphoma, radiotherapy is used to target the whole brain and the eyes. Despite a high response rate of around 50%, radiotherapy, when used alone, does not provide a substantial survival benefit in patients with primary CNS lymphoma, with a median overall survival of 10–18 months and 5-year overall survival of 5%. A phase 2 trial44 that used radiotherapy as first-line treatment was done by the Radiation Therapy Oncology
Consolidation radiotherapy
Although not formally compared in a randomised trial, results of several studies18, 45, 46, 47, 48, 49, 50, 51, 52, 53 suggest that the combination of high-dose methotrexate with radiotherapy is better than radiotherapy alone, in terms of increasing the proportion of long-term survivors (5-year survival 20–50%) (class IIb, class IIIa, class IIIb) and overall survival by two to four times (median 30–72 months). By contrast with extracerebral non-Hodgkin lymphoma, the optimum dose of
Reduced-dose consolidation radiotherapy
Since not giving consolidation WBRT for patients with complete response to chemotherapy is controversial, reduced-dose WBRT is an alternative approach, particularly for patients younger than 60 years who are at a lower risk of developing neurotoxic effects. In a subset analysis65 from a phase 2 trial that included 25 patients younger than 60 years who achieved a complete response after initial chemotherapy and received either 45 Gy or 30·6 Gy as consolidation treatment, patients who received
High-dose chemotherapy, myeloablative conditioning, and autologous stem-cell transplantation
High-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT) is the standard treatment for chemosensitive systemic relapsing diffuse large B-cell lymphomas. However, there is only one multicentre phase 2 trial67 investigating this treatment in patients with relapsed or refractory primary CNS lymphoma, in which a thiotepa, busulfan, cyclophosphamide conditioning regimen was used, followed by ASCT. 27 (63%) of 43 patients completed the full HDC-ASCT procedure, of whom 60% achieved
Elderly patients
Although the definition of elderly is non-uniform within the literature, studies that have assessed prognostic factors have consistently correlated older age (over 50 or 60 years) with poorer outcome (appendix). Furthermore, older age (greater than 60 years) was associated with a higher risk of neurotoxic effects of chemoradiation (appendix). Therefore, 60 years of age was used as a cutoff to define the elderly population in most of the studies that we examined.
Four prospective studies37, 64, 77
Salvage treatment
About a third of patients with primary CNS lymphoma will present with disease that is refractory to first-line treatment and half of responders will relapse despite the high proportion of patients who respond to initial treatment. The prognosis of progressive or relapsed primary CNS lymphoma is poor, with few treatment options. Salvage treatments for patients with relapsed or refractory primary CNS lymphoma depend on age, performance status, site of relapse within the CNS, previous treatments,
Conclusion
Our guidelines represent the state of knowledge at the time of writing. The European Association for Neuro-Oncology website will provide future updates on these guidelines.
References (100)
- et al.
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
Lancet
(2009) - et al.
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Lancet Oncol
(2010) - et al.
Methotrexate and temozolomide versus methotreaxate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in the elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial
Lancet Haematol
(2015) - et al.
Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases
Eur J Surg Oncol
(2005) - et al.
Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?
Int J Radiat Oncol Biol Phys
(1995) - et al.
Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly
Ann Oncol
(2011) - et al.
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
Blood
(2013) - et al.
Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315
Int J Radiat Oncol Biol Phys
(1992) - et al.
The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression
Blood
(1995) - et al.
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Ann Oncol
(2010)
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial
Radiother Oncol
Whole-brain radiotherapy in primary CNS lymphoma
Lancet Oncol
Consolidation radiotherapy in primary CNS lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy
Int J Radiat Oncol Biol Phys
Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study
Ann Oncol
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study
Ann Oncol
Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51
Int J Radiat Oncol Biol Phys
High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma
Ann Oncol
Prospective trial on topotecan salvage therapy in primary CNS lymphoma
Ann Oncol
Primary diffuse large B-cell lymphoma of the CNS
Decreasing incidence rates of primary central nervous system lymphoma
Cancer
Increasing age at diagnosis and worsening renal function in patients with primary central nervous system lymphoma
J Neurooncol
Age, gender, and racial differences in incidence and survival in primary CNS lymphoma
Br J Cancer
The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma
Am J Hematol
Primary malignant lymphomas of the central nervous system
Cancer
Primary intracerebral malignant lymphoma: a report of 248 cases
J Neurosurg
Primary CNS lymphoma: a whole-brain disease?
Neurology
Surgery for primary CNS lymphoma? Challenging a paradigm
Neuro Oncol
Pre-irradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD) for PCNSL: initial report of Radiation Therapy Oncology Group (RTOG) protocol 88-06
J Clin Oncol
A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy
Cancer
Rapid infusion of high-dose methotrexate resulting in enhanced penetration into CSF and intensified tumour response in PCNSL
J Neurosurg
Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome
J Neurosurg
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome
J Clin Oncol
German Cancer Society Neuro-Oncology Working Group NOA-03 multicentre trial of single agent high dose methotrexate for primary CNS lymphoma
Ann Neurol
Treatment of primary cerebral lymphoma with methotrexate and deferred radiotherapy: report of NABTT 96-07
J Clin Oncol
Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)
Cochrane Database Syst Rev
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)
J Clin Oncol
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination
Oncologist
Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid
J Clin Oncol
Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function
J Clin Oncol
Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma
Neurosurgery
Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience
J Clin Oncol
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years
Neurology
Multicenter study of treatment of primary CNS lymphoma
Neurology
Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
J Neurooncol
Prophylactic intrathecal chemotherapy in primary CNS lymphoma
J Neurooncol
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy
J Clin Oncol
Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study
J Neurooncol
Rituximab monotherapy for patients with recurrent primary CNS lymphoma
Neurology
High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma
Neuro Oncol
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy
Hematol Oncol
Cited by (310)
Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluid
2023, Cell Reports MedicineChallenges in the management of primary central nervous system lymphoma
2023, Critical Reviews in Oncology/HematologyModern PET-Guided Radiotherapy Planning and Treatment for Malignant Lymphoma
2023, Seminars in Nuclear MedicineThe role of radiotherapy in newly diagnosed primary CNS lymphoma: A descriptive review and a pragmatic approach to clinical practice
2023, Clinical and Translational Radiation OncologyCSF biomarkers in primary CNS lymphoma
2023, Revue Neurologique